Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

Unit 2 – Comorbidities and complications: Diabetic retinopathy: Fundamentals for primary care

Diabetic retinopathy is a leading cause of visual impairment in the Western world. Its pathophysiology involves a complex inter-related sequence of events giving rise to clinical signs that can predict the risk of visual loss. Risk factors for the development and progression of diabetic retinopathy are clear and guidelines for their management have been made. With good management of the underlying diabetes, regular screening and optimal treatment it is possible to reduce the risk of visual impairment for people with diabetes.

To complete the CPD module, click here.

Diabetic retinopathy remains one of the leading causes of visual impairment – particularly in people of working age – in the industrialised world. In 2014, the World Health Organization (WHO) estimated that there were 285 million visually impaired people in the world, of whom 39 million were blind. Globally, about 80% of all visual impairment could be prevented or cured (WHO, 2014). According to WHO (2015), 1% of global blindness can be attributed to diabetes mellitus.

In the late 1980s, the WHO and International Diabetes Federation (1989) developed the “St Vincent Declaration” as a benchmark for the planning of future delivery of diabetes care. Specific targets were included for the prevention of costly complications, including “a reduction of new cases of blindness by ⅓ in the 5 years after 1990.”

In November 2005, a European conference took place in Liverpool to review progress since the publication of the St Vincent target and to develop a new declaration – the “Liverpool Declaration” (Screening for Diabetic Retinopathy in Europe, 2006). The Liverpool Declaration stated that European countries should reduce the risk of visual impairment due to diabetic retinopathy by 2010 through:

  • Systematic programmes of screening reaching at least 80% of the population with diabetes.
  • The use of trained professionals and personnel.
  • Universal access to laser therapy.

The impact of the complexity of living with diabetes on the individual is extremely important and yet often overlooked by healthcare professionals who, for the best of reasons, tend to concentrate on the objective measures of control. People with diabetes and visual impairment may find it difficult to exercise or may be afraid of the effect that aerobic exercise may have on their eye condition. They cannot follow an appropriate diet if they are not able to get to the shops, to read the labels on food items or to see well enough to cook. And if they cannot see they may not be able to draw up their insulin or self-monitor their blood glucose levels. Loss of independence and reliance on others causes some individuals to avoid activities that they had previously enjoyed.

It is essential for practitioners to understand the underlying pathophysiology of diabetic retinopathy and how it relates to vision and potential treatments. It is also vital to consider the effect this can have on people’s lives, their fears and their expectations.

Box 1 provides a short glossary of terms and Figure 1 gives a schematic diagram of the eye. For an outline of the pathophysiology of diabetic retinopathy, readers are referred to the first version of this module (Broadbent, 2010).

Classification
Diabetic retinopathy is the collective term for the characteristic features seen in the retina directly attributable to diabetes. For the purposes of classification the changes are subdivided into maculopathy (specific diabetes-related damage to the macula) and retinopathy (diabetes-related damage to the whole retina).

Many classification systems have been devised over the years. The system recognised as being the ultimate one was developed for use in seminal research studies, primarily conducted in the US, from which our knowledge of diabetic eye changes has derived. Based on seven-field stereophotography, the Modified Airlie House Classification was instrumental for the documentation of retinal signs in the Early Treatment Diabetic Retinopathy Study ([ETDRS] ETDRS Research Group, 1991b). This is still used today in research and intervention studies all over the world. However, it is extremely complicated and not suited to routine clinical use. As the “gold standard”, all other grading classifications should map to the ETDRS classification.

In the UK each devolved nation has set up a systematic national screening programme (English National Screening Programme for Diabetic Retinopathy [ENSPDR], 2006 – now termed NHS Diabetic Eye Screening Programme [NDESP]; Diabetic Retinopathy Screening Service for Wales [DRSSW], 2016; Scottish Diabetic Retinopathy Screening [SDRS] Collaborative, 2016; Northern Ireland Diabetic Retinopathy Screening Programme [NIDRSP], NIDirect, 2010) and developed similar grading classifications based on the ETDRS system. Grading is based on retinal photographs and is a reporting, rather than a clinical, classification.

The Royal College of Ophthalmologists (2012) also provides clinical guidelines on diabetic retinopathy. In this guidance maculopathy is divided into:

  • Focal: well-confined areas of leakage (often from microaneurysms) with hard exudates in complete or incomplete “circinate” rings (see Figure 2).
  • Diffuse: generalised intraretinal oedema, often without exudates and due to capillary leakage (with or without retinal pigment epithelium pump failure or vitreomacular traction).
  • Ischaemic: often relatively normal appearance or minimal oedema and poor vision. Fundus fluorescein angiography reveals capillary fall-out.
  • Mixed.

Many cases of maculopathy fall into the mixed category but it is useful for treatment purposes to classify them into the category with the most predominant features.

A simplified version of the ETDRS classification aimed at countries without systematic screening programmes has also been developed by the American Academy of Ophthalmology Guidelines Committee (Wilkinson et al, 2003). Table 1 shows the classification of diabetic retinopathy used in NDESP.

Prevalence and incidence
The prevalence and incidence of diabetic retinopathy are explored in detail in the first version of this module (Broadbent, 2010).

Risk factors
The most important treatment for diabetic retinopathy is control of the underlying diabetes. Good management of diabetes can prevent the development, and slow the progression of, diabetic retinopathy (relevant data are explored below). Primary care physicians and practice nurses play a key role in the regular measurement and target-based treatment of modifiable risk factors.

Risk factors for the development and progression of diabetic retinopathy can be either modifiable or unmodifiable. The most important modifiable factors are glycaemia and blood pressure.

Both the DCCT (Diabetes Control and Complications Trial; DCCT Research Group, 1993; 1995a; 1995b; 2002) in type 1 diabetes and the UKPDS (UK Prospective Diabetes Study; UKPDS Group, 1998) in type 2 diabetes have shown a clear relationship between the duration of diabetes and glycaemic control in the development of retinopathy.

In the DCCT (1993), intensive glycaemic control (median HbA1c level of 56 mmol/mol [7.3%] versus 76 mmol/mol [9.1%] in the conventional group) conferred a 76% risk reduction in development of retinopathy in those without retinopathy at baseline, and a 47% reduction in progression to severe non-proliferative diabetic retinopathy (non-PDR) or PDR for those with established retinopathy at baseline. However, they also reported an increase in extra hypoglycaemic episodes requiring assistance of 43 per 100 patient years in the intensive control group. Metabolic memory is a term used to describe beneficial effects of immediate intensive treatment of hyperglycaemia and the observation that they are maintained for many years, regardless of glycaemia in the later course of diabetes.

In the UKPDS, a median HbA1c of 53 mmol/mol (7.0%) compared to 63 mmol/mol (7.9%) resulted in a 34% reduction in the development of diabetic retinopathy and a 17% reduction in progression (UKPDS Group, 1998).

The UKPDS primarily considered blood pressure and found that tight control of blood pressure resulted in a 37% reduction in microvascular complications and a 47% reduction in loss of vision by 3 lines or more on the ETDRS vision chart. Over a quarter of individuals (29%) required three or more medications to reach the target blood pressure. They did not find any difference between the use of beta-blockers and angiotensin-converting-enzyme (ACE) inhibitors. EUCLID (the European Controlled Trial of Lisinopril in Insulin-Dependent Diabetes; Chaturvedi et al, 1998) suggested that blockade of the renin–angiotensin system (using ACE inhibitors) might be superior to beta-blockade. However, the study was not designed to specifically address this question and was, consequently, under-powered.

The selective effect of an angiotensin receptor blocker is theoretically superior to ACE inhibition. The DIRECT (Diabetic Retinopathy Candesartan Trials) programme has suggested that candesartan can reduce the incidence of any retinopathy in people with type 1 diabetes and induce regression of retinopathy in people with type 2 diabetes, although the study just failed to reach statistical significance (Chaturvedi et al, 2008; Sjølie et al, 2008).

Both WESDR (the Wisconsin Epidemiological Study of Diabetic Retinopathy) and the Hoorn study (van Leiden et al, 2002) have shown a correlation between high blood cholesterol levels and risk of retinopathy in people with diabetes. A theoretical role for lipids in the development of retinopathy has been proposed and a clearing of retinal exudates has been observed in people receiving statins, but it is not yet completely clear whether this is an unloading effect or a therapeutic effect. The more recent FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study did show a significant reduction in the need for laser treatment in people with type 2 diabetes (37% reduction in laser overall, 31% for first laser for maculopathy, and 30% for PDR) receiving fenofibrate (Keech et al, 2007; Wright and Dodson, 2011). This occurrence appeared to be independent of a lipid-lowering effect, and a protein kinase C (PKC) inhibition mechanism was proposed. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Eye study also showed a significant reduction in diabetic retinopathy progression in the fenofibrate group independent of glycaemia and a 40% reduction in odds of having progression in diabetic retinopathy over 4 years with fenofibrate plus simvastatin versus placebo (ACCORD Study Group and ACCORD Eye Study Group, 2010; Chew and Ambrosius, 2011; Wright and Dodson, 2011). However, fenofibrate does have an effect on creatinine, the mechanism for which is unclear at present. Practically, if an individual is to be considered for fenofibrate because of sight-threatening diabetic retinopathy he or she should be on the maximum tolerated statin dose before the fibrate is prescribed and then renal and liver function should be monitored closely.

Anecdotally, practitioners can all recount individuals with immaculate metabolic control and aggressive retinopathy, and conversely individuals with many years of poor control and no retinopathy. It is very probable that there is a genetic explanation for this. Not surprisingly, there have been extensive studies; however, to date, no single gene has been identified (Hanis and Hallman, 2006). The biological processes underlying the development of retinopathy are complex and inter-related. It would be foolish to suppose that there would not be similarly complex relationships between many genes, with small inter-related effects, and the environment.

One of the recommendations of the Liverpool Declaration was to promote joint working between ophthalmologists, diabetologists and primary care. A joint meeting was held in Liverpool in November 2007. Consensus guidelines for management of risk factors were developed and are presented in Table 2. However, it should be recognised that there is a need for individualised targets based on an assessment of relevant risks and benefits.

Screening
Screening for diabetic retinopathy in the UK meets the requirements set out in the World Health Organization document titled Principles and Practice of Screening for Disease (Wilson and Jungner, 1968).

Following the St Vincent Declaration and a joint workshop of the UK National Screening Programme and the Royal College of Ophthalmologists in October 1999, recommendations for the implementation of national screening programmes for diabetic retinopathy in the UK were made. The National Service Framework for Diabetes stated that: “by [March] 2006, a minimum of 80% of people with diabetes are to be offered screening for the early detection (and treatment if needed) of diabetic retinopathy as part of a systematic programme that meets national standards, rising to 100% coverage of those at risk of retinopathy by end 2007” (Department of Health, 2003).

National programmes with this aim but slightly different operational procedures have now been implemented in all four devolved nations (NDESP, 2015; DRSSW, 2016; NIDirect, 2016; SDRS, 2016). All use digital photography as the method of choice as this is the only method that meets the Exeter targets for sensitivity (80%) and specificity (95%) – as described by Taylor et al (1998) – and allows appropriate quality assurance. Screening, however, is a “sieve”. No method currently achieves 100% sensitivity and specificity, although screening can reduce the risk of vision loss to an acceptable rate. For this reason, quality-assurance targets for the process have been set and programmes must meet Key Performance Indicators. Quality assurance is the safety net that underpins any screening programme, and all programmes are measured against service objectives. The management of screen-positive cases in the NDESP is provided in Table 3.

Currently, all people with diabetes aged 12 years and over in the UK are eligible for annual screening unless they have no perception of light in either eye. Exclusions from screening in England include the following groups of people (NDESP, 2012):

  • Those who have made a written informed choice to opt out of NDESP. These people should be contacted again by the screening programme after 3 years to ascertain whether they still wish to be opted out of screening.
  • Those who would never be able to receive or benefit from treatment owing to another existing condition. This includes people who are terminally ill.
  • Those who have been assessed by the clinical lead for the local screening programme as never being able to be screened by digital photography or slit-lamp biomicroscopy.

People who are excluded are not invited for screening and are not screened or assessed for diabetic retinopathy.

Eligible people who continue to have their retinas checked for diabetic retinopathy can be suspended from screening if they are in one of the following states:

  • Under the care of the hospital eye service (HES) for the management or treatment of diabetic retinopathy.
  • Under surveillance for diabetic retinopathy in either a slit-lamp biomicroscopy clinic (those who have ungradable or unobtainable images) or a digital imaging surveillance clinic (community or hospital-based). Digital Surveillance clinics allow people with early disease (pre-treatment) to be monitored more frequently than annually. This is at the discretion of the ophthalmic clinical lead.

All screening programmes are expected to implement fail-safe mechanisms. Fail-safe is a back-up mechanism so that when something goes wrong in a system, processes are in place to identify what is going wrong and action follows to ensure that there is a safe outcome. Responsibilities for stakeholders have been identified. People who are suspended should be monitored through the fail-safe system in the screening programme.

Pregnancy and comorbidities
Pregnant women with either type 1 or type 2 diabetes should be offered digital photography in a digital surveillance clinic at (or soon after) their first antenatal clinic visit and again at 28 weeks’ gestation. If background diabetic retinopathy is found to be present, an additional screen should be performed at 16–20 weeks and for at least 6 months post-partum. If sight-threatening diabetic retinopathy develops during the pregnancy, the individual should be referred to the HES (NDESP, 2016).

People with diabetes and comorbidities visiting an ophthalmologist should also have  photographs taken for diabetic retinopathy screening (ideally as part of their appointment, but at a separate appointment if this is not possible). If there are reasons why this photography is likely to be unsuccessful (ungradable or unobtainable images), they should be “screened” for diabetic retinopathy using slit-lamp biomicroscopy as part of their routine ophthalmic appointment.

Mobility issues, prisons and non-compliance
Confusion often arises with regard to house-bound individuals. Screening programmes should provide local solutions to mobility issues, such as arranging direct referral to a slit-lamp biomicroscopy clinic. Those who are physically unable to comply with treatment for diabetic retinopathy (i.e. unable to attend an ophthalmic clinic) are covered as part of the exclusion criteria (NDESP, 2012).

People with diabetes who are currently in prison in the UK should be included in the screening programme of the clinical commissioning group responsible for healthcare in that facility. These individuals pose particular problems with regard to mobility of the population and confidentiality. Ideally, prison populations should be screened every 6 months to ensure adequate coverage (NDESP, 2012).

Non-compliance with screening can be a major problem. Leese et al (2008) identified an association between non-attendance at screening with living in socially deprived areas, poor glycaemic control, higher blood pressure, smoking, longer duration of disease and earlier age, although a recent paper exploring screening in three South London boroughs suggested that socio-economic inequality might be smaller than reported in earlier studies (Gulliford et al, 2010). In this study, the highest non-attendance rates were in adults aged 18–34 (32%) and in the people 85 years and older (28%). Psychological factors clearly play a large part and although mechanisms to improve uptake can be effective they require intense effort and resources. The recommendation is that people should be given two opportunities to attend. If they fail to keep these appointments, the GP should be informed and advised that further appointments will not be routinely offered and the individual will be temporarily suspended from screening. Appointments will be offered again in the next screening year (NDESP, 2012).

Practical aspects
People attending for screening should bring all their current glasses and, particularly on sunny days, a pair of dark glasses for use until the eye drops wear off. Usually, only a short-acting eye drop is used to dilate the pupils. This wears off after 2–3 hours. Near vision is affected more than distance vision, but people should be advised not to drive during this time. In the HES setting, and occasionally in screening, longer-acting eye drops are needed, blurring vision for 6–12 hours. There is a small risk of provoking angle-closure glaucoma by dilating the pupils in susceptible individuals, and all attendees should be given a warning letter about this. Open angle glaucoma or treated closed angle glaucoma is not a contra-indication to screening (Wolfs et al, 1997).

Evidence for benefits
An article from Sweden in 2007 demonstrated that a reduction of blindness due to diabetes can be achieved, but that it requires a combination of careful screening for diabetes, effective screening for diabetic retinopathy and good medical management (Olafsdottir et al, 2007).

Also in Sweden, biennial screen intervals have been adopted for people without retinopathy for some time (Stefansson et al, 2000). A study carried out in Malmö (Agardh et al, 2011) prospectively followed people with type 2 diabetes and no retinopathy and concluded that it appeared safe to adopt 3-year intervals, as suggested by the Liverpool group (Younis et al, 2003a; 2003b). However, the participants were compliant (only 9% did not attend for follow-up), they had a short duration of diabetes (6±6 years [mean ± standard deviation]) and good control (HbA1c, 46.0±16.4 mmol/mol [6.4±1.5%] at baseline and 45.0±14.2 mmol/mol [6.3±1.3%] at 3-year follow-up), and consequently it might be unwise to recommend 3-year intervals for all people with diabetes, without further studies. Additionally, it is vital to ensure that grading is highly accurate in order to ensure that the appropriate screen interval is chosen. It is likely that, in the future, economic drivers will lead to the introduction of biennial screening in individuals with no retinopathy. There are current research trials assessing screen intervals based on individual risk.

Although all patients in England are currently recalled annually for screening, an NIHR programme grant incorporating a randomised controlled trial, the ISDR study, is implementing risk-based screening intervals in Liverpool (NIHR, 2013).

Quality and Outcomes Framework (QOF)
The QOF indicator for retinopathy screening was retired from the diabetes domain in England and Northern Ireland in 2013 (Kenny, 2014). In 2014, the indicator was also retired in Wales (NHS Wales, 2014) and Scotland (ISD Scotland, 2014). Screening was removed from the Framework as it was deemed standard practice. Practices should ensure new patients are referred and that defaulters are encouraged to attend (NHS Employers, 2015).

Public health considerations
Local strategies to promote awareness of the programme and the importance of screening, and to highlight the benefits of attendance, thus encouraging the uptake of appointments, should be an integral part of any systematic screening programme.

A public health-orientated service specification for the NDESP has been published (NDESP, 2015) and all screening services in England now come under the remit of Public Health England, with services in Wales managed by Public Health Wales. This document states clearly the essential elements to be met by every screening programme in the NDESP. It should not be forgotten that primary care health professionals have an equally important role to play. They should:

  • Provide the screening programme with accurate and timely updates on the demographic data of their diabetes population (e.g. newly diagnosed, died, moved away).
  • Regularly monitor risk factors in the people with diabetes they see and strive for optimal control (as in Table 2).
  • Monitor non-compliance with screening and actively encourage engagement.
  • Be in regular communication with the screening programme and assist in developing service improvements.

Ophthalmic treatment
Laser treatment: How does laser treatment work?
It is not completely clear how laser treatment acts but it is believed that by producing a thermal coagulation of the retinal pigment epithelium (RPE) and adjacent retinal layers, the amount of retinal tissue is reduced leading to an improvement in perfusion and oxygenation. It also modifies gene expression mediated by the healing response of the RPE to thermal injury and reduces vascular endothelial growth factor (VEGF) production. Maculopathy laser treatment can also be used to directly ablate leaking microaneurysms (although this holds the risk of producing a choroidal neovascular membrane by causing a break in Bruch’s membrane between the retina and the underlying choroid if the power is too high) and, when applied as a grid over areas of oedema, acts to improve the “RPE pump”, which actively removes fluid from the retina. With time, laser scars too close to the foveola may spread and obliterate the central vision. Laser treatment can stabilise the retinal changes but is rarely able to restore vision that has been lost.

The conventional treatment for diabetic retinopathy to date has been peripheral scatter laser photocoagulation. To be effective, this must be given at the optimal stage of the disease process. Studies have shown that in imminent or early proliferative retinopathy it will prevent severe sight loss in over 90% of cases (Diabetic Retinopathy Study Research Group, 1981). In most cases it is possible to preserve reading and driving vision.

Laser treatment for focal and diffuse maculopathy is not as successful as that for proliferative retinopathy but still prevents serious sight loss in 60–70% of cases (ETDRS Research Group, 1985). Laser treatment is ineffective in ischaemic maculopathy.

Laser treatment is given at an outpatient clinic and may involve a single visit or more than one visit before the eye changes are controlled. Treatment for retinopathy, specifically, is to apply a large number of laser spots (1500–3000 in total) to the peripheral retina. The recently introduced PAtterned SCAnning Laser (PASCAL) system allows semi-automated application of arrays of gentle laser burns, reducing the treatment time and increasing patient comfort. Most people do notice a problem with night vision after laser treatment but few notice a change in their field of vision.

In the UK, the Driver and Vehicle Licensing Agency (DVLA) has set standards of visual field function that are required for permission to hold a driver’s licence (DVLA, 2013). In the UK, it is the individual’s responsibility to inform the DVLA that he or she has had laser therapy for diabetic retinopathy. If this is not possible, then the individual’s next of kin or GP should inform the DVLA of the person’s visual status.

In the treatment for maculopathy, gentle laser burns are applied close to the centre of the fovea. A much lower exposure to laser is required than for retinopathy. Complications for this type of treatment are rare.

Although laser treatment can be effective, worldwide the search for newer, more effective or less destructive treatments continues.

Pharmacological approaches
Laser treatment remains the treatment of choice for proliferative retinopathy. However, there is now compelling evidence from randomised controlled trials for the use of intravitreal injections in the treatment of diabetic maculopathy.

A number of important studies have shown that injections of steroid drugs, such as triamcinolone and fluocinolone, directly into the eye, are effective at treating diabetic maculopathy (Rudnisky et al, 2009). More recent studies have included dexamethasone intravitreal implant (Boyer et al, 2014). However, the effect wears off and injections need to be repeated every 6 months. Important potential side effects of this treatment are the development of glaucoma and cataract. There is a development rate for glaucoma of 25–40%, with a peak at 2 months. In most cases, intraocular pressure returns to normal at 4–6 months; however, around 2% will need glaucoma surgery (for a review of this topic see Razeghinejad and Katz [2012]).

Anti-VEGF agents have been investigated for some time as an alternative to conventional laser treatment, particularly for diabetic maculopathy. Oral PKC inhibitors have been studied and shown to have an effect in certain groups of people (Aiello et al, 2006), but the main focus is now on the intravitreal injection of anti-VEGF agents (ranibizumab, bevacizumab and aflibercept). Results are temporary, requiring repeated injections at monthly intervals, but these agents have been shown to be superior to laser treatment when the vision has been affected (Elman et al, 2010; 2012; Diabetic Retinopathy Clinical Research (DRCR) Network, 2011; Mitchell et al, 2011; Rajendram et al, 2012).

There is a small but as yet undetermined risk of promoting arterial thromboembolic events with the use of anti-VEGF agents and caution must be exercised in people with a recent history of a cardiovascular event. The agents are also contraindicated in pregnancy (e.g. electronic Medicines Compendium, 2013). Finally, all injections directly into the eye hold a small risk of the development of endophthalmitis (a serious infection inside the eye). This risk has been estimated to be approximately 0.05% in a meta-analysis of over 100000 injections (Ueta et al, 2009). Following ranibizumab intravitreal injections in the DRCR.net studies, a prevalence of 0.9% endophthalmitis was reported, with no cases after intravitreal triamcinolone (Bhavsar et al, 2009).

On 27 February 2013, NICE approved ranibizumab for the treatment of diabetic macular oedema (DMO) in people with visual impairment and significant oedema (≥400 µm on optical coherence tomography). The body suggested monthly injections until the vision was stable for 3 months and resumption if the vision dropped again (NICE, 2013a). The Scottish Medicines Consortium (2012) brought in similar guidance for Scotland shortly before this.

In November 2013, NICE also approved the use of fluocinolone (Iluvien) for patients with chronic oedema resistant to other treatments who had undergone cataract surgery (NICE, 2013b) and in July 2015 the use of aflibercept (Eylea) for patients with DMO ≥400 µm on optical coherence tomography (NICE, 2015).

Surgical vitrectomy
Surgical vitrectomy has been the treatment of choice for people with advanced retinopathy (vitreous haemorrhage and traction retinal detachment). It has also been shown to have good results in tractional diabetic maculopathy (Haller et al, 2010). An area of increasing interest lies in the possibility of giving an injection into the eye to produce a chemical vitrectomy, particularly for maculopathy, and this is being actively researched.

Treatment summary
In summary, peripheral scatter laser treatment remains the treatment of choice for imminent or early proliferative retinopathy. A rational approach to treatment for diabetic maculopathy includes the following:

  • Monitor closely if there is good vision and the individual is asymptomatic.
  • Consider laser treatment for sight-threatening maculopathy with good vision or minimal reduction in visual acuity and minimal oedema.
  • If there is reduced vision and significant oedema, inject an intravitreal anti-VEGF agent for monthly 3 months, assess response and consider further anti-VEGF or laser treatment.
  • If pseudophakic (post-cataract surgery), consider intravitreal steroid.

Conclusion
Diabetic retinopathy is one of the most feared complications of diabetes, but evidence clearly shows that the risk of visual impairment can be significantly reduced with good control of diabetes, regular screening and timely treatment.

Primary care practitioners play a key role in the regular measurement and treatment of modifiable risk factors for diabetic retinopathy, and in ensuring that people with diabetes attend regularly for screening.

Take-home messages

  • HbA1c <53 mmol/mol (7%) reduces risk of development and worsening of diabetic retinopathy.
  • HbA1c <48 mmol/mol (6.5%) does not confer further benefit and in

ACCORD Study Group, ACCORD Eye Study Group (2010) N Engl J Med 363: 233–44
Agardh E, Tabayat-Khani P (2011) Diabetes Care 34: 1318–9
Aiello LP, Davis MD, Girach A et al (2006) Ophthalmology 113: 2221–30
Bhavsar AR, Googe JM Jr, Stockdale CR et al (2009) Arch Ophthalmol 127: 1581–3
Boyer DS, Yoon YH, Belfort R Jr et al (2014) Ophthalmology 121: 1904–14
Broadbent D (2010) Diabetes & Primary Care 12: 34–44
Chaturvedi N, Sjolie AK, Stephenson JM et al (1998) Lancet 351: 28–31
Chaturvedi N, Porta M, Klein R et al (2008) Lancet 372: 1394–402
Chew EY, Ambrosius WT (2011) Update of the ACCORD Eye Study. N Engl J Med 364: 188–9
DCCT Research Group (1993) N Engl J Med 329: 977–86
DCCT Research Group (1995a) Diabetes 44: 968–83
DCCT Research Group (1995b) Ophthalmology 102: 647–61
DCCT Research Group (2002) JAMA 287: 2563–9
Department of Health (2003) National Service Framework for Diabetes: Delivery Strategy. DoH, London
Diabetic Retinopathy Clinical Research Network (2011) Ophthalmology 118: 609–14
Diabetic Retinopathy Screening Service for Wales (2016) Welcome to the Diabetic Retinopathy Screening Service for Wales (DRSSW).University Health Board, Cardiff. Available at: http://www.cardiffandvaleuhb.wales.nhs.uk/drssw (accessed 25.01.16)
Diabetic Retinopathy Study Research Group (1981) Ophthalmology 88: 583–600
Driver and Vehicle Licensing Agency (2013) At a glance Guide to the current Medical Standards of Fitness to Drive. DVLA, Swansea. Available at: http://bit.ly/11g0PGq (accessed 24.07.13)
electronic Medicines Compendium (2013) Lucentis 10 mg/ml solution for injection. eMC, Leatherhead. Available at: medicines.org.uk/emc/medicine/19409 (accessed 24.07.13)
Elman MJ, Aiello LP, Beck RW et al (2010) Ophthalmology 117: 1064–77
Elman MJ, Oin H, Aiello LP et al (2012) Ophthalmology 119: 2312–8
English National Screening Programme for Diabetic Retinopathy (2006) UK National Screening Committee: Essential Elements in Developing a Diabetic Retinopathy Screening Programme. Appendix 1: NSC Retinopathy Grading Standard. ENSPDR, London
ETDRS Research Group (1985) Arch Ophthalmol 103: 1796–806
ETDRS Research Group (1991a) Ophthalmology 98(5 Suppl): 823–33
ETDRS Research Group (1991b) Ophthalmology 98(5 Suppl): 786–806
Gulliford MC, Dodhis H, Chamley M et al (2010) Diabet Med 27: 282–8
Haller JA, Qin H, Apte RS, Diabetic Retinopathy Clinical Research Network Writing Committee (2010) Ophthalmology 117: 1087–93
Hanis CL, Hallman DM (2006) Curr Diab Rep 6: 155–61
ISD Scotland (2014) Quality and Outcomes Framework: Revisions to the QOF, by year. Information Services Division, Edinburgh. Available at: http://www.isdscotland.org/Health-Topics/General-Practice/Quality-And-Outcomes-Framework/Revisions-To-QOF.asp (accessed 24.03.16)
Keech AC, Mitchell P, Summainen PA et al (2007) Lancet 370: 1687–97
Kenny C (2014) Diabetes & Primary Care 16: 55–8
Leese GP, Boyle P, Feng Z et al (2008) Diabetes Care 31: 2131–5
Mitchell P, Bandello F, Schmidt-Erfurth et al (2011) Ophthalmology 118: 615–25
NHS Diabetic Eye Screening (DES) programme (2012) Diabetic Eye Screening: screening exclusions and suspensions and, managing ungradable images. Available at: http://www.gov.uk/government/publications/diabetic-eye-screening-screening-exclusions-and-suspensions-and-managing-ungradable-images (accessed 25.10.16)
NHS Diabetic Eye Screening (DES) programme (2015) Population screening programmes. Available at: https://www.gov.uk/topic/population-screening-programmes/diabetic-eye (accessed 25.01.16)
NHS Diabetic Eye Screening (DES) programme (2016) Screening tests for you and your baby. Available at: https://www.gov.uk/governmenthttps://www.diabetesonthenet.com/uploads/systemhttps://www.diabetesonthenet.com/uploads/attachment_data/file/440859/STFYAYB_010715_web_ready.pdf (accessed 25.01.16)
NHS Employers (2015) 2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF) Guidance for GMS contract 2015/16. NHS Employers, Leeds
NHS Wales (2014) Annex 1: Changes to the Quality and Outcomes Framework: 2014/15. Available at: http://www.wales.nhs.uk/sites3/documents/480/GMS%20Contract%202014%2015%20QOF%20Changes%2010%20January%202014.pdf (accessed 24.03.16)
NICE (2013a) Macular oedema (diabetic) – ranibizumab (TA274). NICE, London. Available at: http://www.nice.org.uk/ta274 (accessed 24.07.13)
NICE (2013b) Macular oedema (diabetic) – fluocinolone acetonide (TA301). NICE, London. Available at: https://www.nice.org.uk/guidance/ta301 (accessed 25.01.16)
NICE (2015) Macular oedema (diabetic) – aflibercept (TA346). NICE, London. Available at: https://www.nice.org.uk/guidance/ta346 (accessed 25.01.16)
NIDirect (2016) Diabetic Retinopathy Screening. Public Health Agency, Belfast. Available at: http://www.nidirect.gov.uk/diabetic-retinopathy-screening (accessed 25.01.16)
NIHR (2013) Introducing personalised risk based intervals in screening for diabetic retinopathy: development, implementation and assessment of safety and patient experience. NIHR, London. Available at: http://www.nihr.ac.uk/funding/funded-research/funded-research.htm?postid=2249 (accessed 11.03.16)
Olafsdottir E, Andersson DK, Stefansson E (2007) Acta Ophthalmol Scand 85: 40–5
Rajendram R, Fraser-Bell S, Kaines et al (2012) DRCR net Arch Ophthalmol 130: 972–9
Razeghinejad MR, Katz LJ (2012) Ophthalmic Res 47: 66–80
Royal College of Ophthalmologists (2012) Diabetic Retinopathy Guidelines 2012. RCOphth, London.
Rudnisky CJ, Lavergne V, Katz D (2009) Can J Ophthalmol 44: 587–93
Screening for Diabetic Retinopathy in Europe (2006) Screening for Diabetic Retinopathy in Europe: 15 years after the St. Vincent Declaration. The Liverpool Declaration 2005. Royal Liverpool University Hospital, Liverpool
Scottish Diabetic Retinopathy Screening Collaborative (2016) Welcome to the Scottish DRS Collaborative. NHS Scotland, Edinburgh. Available at: http://www.ndrs.scot.nhs.uk (accessed 25.01.16)
Scottish Medicines Consortium (2012) Ranibizumab (Lucentis). SMC, Glasgow. Available at: http://bit.ly/1c5F3cU (accessed 24.07.13)
Sjølie AK, Klein R, Porta M et al (2008) Lancet 372: 1385–93
Stefansson E, Bek T, Porta M et al (2000) Acta Ophthalmol Scand 78: 374–85
Taylor R, Broadbent DM, Greenwood R et al (1998) Diabet Med 15: 344–7
Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T (2009) Ophthalmology 116: 362
UK Prospective Diabetes Study Group (1998) BMJ 317: 703–13
van Leiden HA, Dekker JM, Moll AC et al (2002) Diabetes Care 25: 1320–5
Wilkinson CP, Ferris FL, Klein R et al (2003) Ophthalmology 110: 1677–82
Wilson JM, Jungner YG (1968) Principles and Practice of Screening for Disease. World Health Organization, Geneva, Switzerland. Available at: http://whqlibdoc.who.int/php/WHO_PHP_34.pdf (accessed 24.07.13)
Wolfs RC, Grobbee DE, Hofman A, de Jong PT (1997) Invest Ophthalmol Vis Sci 38: 2683–7
World Health Organization (2014) Visual impairment and Blindness. Fact sheet No 282. Updated August 2014. WHO, Geneva, Switzerland
World Health Organization (2015) Diabetes. Fact sheet No 312. Updated January 2015. WHO, Geneva, Switzerland
World Health Organization, International Diabetes Federation (1989) Diabetes care and research in Europe: The St Vincent Declaration 1989. St Vincent, Italy
Wright AD, Dodson PM (2011) Eye (Lond) 25: 843–9
Younis N, Broadbent DM, Harding SP, Vora JP (2003a) Diabetic Med 20: 758–65
Younis N, Broadbent DM, Vora JP, Harding SP (2003b) Lancet 361: 195–200

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.